and NEW YORK, March 11, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 VERITAC-2 clinical trial NEW ...
Guggenheim analyst Vamil Divan maintained a Buy rating on Pfizer (PFE – Research Report) yesterday. The company’s shares closed yesterday at ...
Pfizer (NYSE:PFE) stock and Arvinas (NASDAQ:ARVN) stock slip in reaction to mixed Phase 3 data for their breast cancer drug ...
The partners will test Summit’s ivonescimab alongside Pfizer’s antibody-drug conjugates in hopes of finding “potentially ...
Arvinas (ARVN) and Pfizer (PFE) announced topline results from the Phase 3 VERITAC-2 clinical trial evaluating vepdegestrant monotherapy versus ...
Sustainalytics’ Controversies Research identifies companies involved in incidents and events that may negatively impact stakeholders, the environment or the company’s operations. Controversies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback